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Abstract
Objective. To estimate the financial and health burden of 
diabetic ambulatory care sensitive hospitalisations (ACSH) 
in Mexico during 2001-2011. Materials and methods. 
We identified ACSH due to diabetic complications in general 
hospitals run by local health ministries and estimated their 
financial cost using diagnostic related groups. The health 
burden estimation assumes that patients would not have 
experienced complications if they had received appropri-
ate primary care and computes the associated Disability-
Adjusted Life Years (DALYs). Results. The financial cost 
of diabetic ACSH increased by 125% in real terms and their 
health burden in 2010 accounted for 4.2% of total DALYs 
associated with diabetes in Mexico. Conclusion. Avoiding 
preventable hospitalisations could free resources within the 
health system for other health purposes. In addition, patients 
with ACSH suffer preventable losses of health that should be 
considered when assessing the performance of any primary 
care intervention. 
Keywords: ambulatory care sensitive hospitalisations; primary 
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Resumen
Objetivos. Estimar la carga financiera y de salud de las 
hospitalizaciones relacionadas con diabetes sensibles a la 
atención ambulatoria (HSAA) en México durante 2001-2011. 
Material y métodos. Se identificaron HSAA relacionadas 
con complicaciones diabéticas en hospitales generales opera-
dos por los servicios estatales de salud y se estimó su costo 
financiero utilizando grupos relacionados por diagnóstico. 
Para estimar la carga de salud se supuso que los pacientes 
no hubieran sufrido complicaciones diabéticas si hubieran 
recibido atención primaria adecuada y se calcularon los años 
de vida ajustados por discapacidad (AVAD). Resultados. 
El costo financiero de las HSAA diabéticas aumentó 125% 
en términos reales y la carga de salud en 2010 representó 
4.2% del total de AVAD asociados con la diabetes en Mé-
xico. Conclusiones. Evitar hospitalizaciones prevenibles 
libera recursos dentro del sistema de salud. Adicionalmente, 
pacientes con HSAA sufren pérdidas de salud prevenibles 
que deben tomarse en cuenta al evaluar el desempeño de la 
atención primaria.
Palabras clave: hospitalizaciones sensibles a la atención am-
bulatoria; atención primaria; diabetes; México
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Timely, effective and high-quality primary care ser-vices can prevent the development or exacerbation 
of some health conditions which may lead to hospitalisa-
tions. These avoidable hospitalisations –ambulatory care 
sensitive hospitalisations (ACSHs)– have been widely 
used to study the access to, quality and effectiveness of 
primary care services.1,2 While the financial implications 
of ACSHs have been studied before for some countries, 
the preventable losses of health as a consequence of 
ACSHs have not received attention in the literature. 
This paper estimates the financial cost of ACSHs in 
public general hospitals in Mexico and proposes a way 
to quantify the health burden associated with them.
 Although the literature on ACSHs is extensive, 
few studies have considered the cost they represent to 
the health system. Culler and colleagues estimated that 
Medicare cost savings from eliminating all potentially 
preventable hospitalisations could have reached 9% of 
the programme’s spending during 1991.3 Analysing 
nursing home data from New York State, Grabowski 
and colleagues found that ACSHs made up 23% of 
total spending on nursing home hospitalisations.4 Kim 
focused on uncontrolled diabetes in the U.S. during 
2004 and estimated that approximately 32% of hospital 
admissions that were primarily a result of diabetes were 
due to uncontrolled diabetes with a cost amounting to 
2.8 billion dollars.5 McFarlane and colleagues estimated 
that “the total economic burden for hospitalisations” for 
diabetes and hypertension represented 1.2% of the recur-
rent budget for the regional health authorities of Jamaica 
in 2010-2011.6 No study appears to have estimated the 
health burden of suffering ACSHs.
 Worldwide, most ACSHs are associated with 
chronic diseases; in Mexico, previous studies show that 
diabetes is the most important cause of ACSH.2,7,8 The 
prevalence of diabetes has risen dramatically during 
recent decades and its high costs and serious health con-
sequences have made it a public health priority.9,10 This 
paper focuses on the costs of five diabetic complications 
assumed to be avoidable through timely and effective 
primary care. 
 The economic burden of diabetes in Mexico has 
been analysed in several studies.10-12 In the most recent 
report, Barraza-Lloréns and colleagues (2015) estimated 
that in 2013 this burden, including direct and indirect 
costs, was MXN$362 859.8 million accounting for 2.25% 
of GDP. Direct costs were estimated as MXN$179 495.3 
million of which medical care for the main diabetic 
complications represented 87%. 
 The health burden of diabetes in 2010 was estimated 
as 1 614 486 DALYs, representing the first and the fourth 
cause of DALYs for females and males, respectively.13 
Clearly diabetes imposes an important pressure on both 
public finance and population health in Mexico, one 
which is expected to increase with the continuing rise 
in the prevalence of diabetes.9 While primary care does 
not necessarily prevent the development of diabetes, ap-
propriate management can prevent the main complica-
tions of the disease. The aim of this paper is, therefore, 
to identify the avoidable component of these burdens as 
an effort to contribute to understanding and improving 
the efficiency with which healthcare resources are used 
in Mexico.
Materials and methods
The analysis uses hospital discharge data for the period 
2001-2011 from general hospitals run by local health 
ministries.14 Data on diagnosis and medical proce-
dures, among other variables, were recorded for each 
discharge, but it is not possible to link patient episodes 
since unique ID numbers are not available.
 Hospitalisations of patients 20 years or older due 
to five complications of diabetes (retinopathy, kidney 
failure, neuropathy and diabetic foot) were identified 
through the ICD-10 code of the main diagnosis in each 
case. If a patient experienced an amputation procedure 
and his main hospitalisation diagnosis was any of the 
ICD-10 codes reported in table I, it was classified as a 
diabetic amputation and also considered in this analysis.
 The economic burden of ACSHs is formed by the 
value of the resources needed to provide this type of 
care instead of using them in other interventions and 
by the effects of an ACSH on the participation and per-
formance in the labour market of those suffering them. 
This study focuses only on the first component using the 
financial cost of the hospital care received. The health 
burden of an ACSH could be represented by the effects 
on the disability suffered by patients with ACSHs that 
would not have been hospitalised if they had received 
appropriate primary care. 
 The hospital discharges database does not include 
cost data that could be used to estimate inpatient day 
costs; hence, this study uses the Diagnostic Related 
Group (DRG) system from the Mexican Institute of 
Social Security (IMSS) to estimate the financial costs of 
ACSH due to diabetic complications in general hospi-
tals run by local health ministries.15 Thus, costs in IMSS 
hospitals are assumed similar to those operated by local 
health ministries. Arredondo and De Icaza estimated, 
however, that IMSS average diabetic hospitalisations 
costs are 1.8 times the costs of the Ministry of Health.9 
They indicate that the difference in costs can be mainly 
explained by differences in case management protocols, 
in productivity standards, in quality standards and in 
cost of inputs. Consequently, this study uses the full 
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IMSS-DRG cost to estimate the upper bound of the 
ACSH financial costs in local health ministries, but also 
presents the results using 56% of the IMSS-DRG costs 
(as suggested by Arredondo and De Icaza). Since IMSS-
DRG data are only available for 2013, the assumption 
is that IMSS-DRG costs only changed due to inflation 
during the study period.
 Some of the ICD-10 codes analysed can be classified 
in more than one DRG; the decision of which DRG to 
use in each case was based on the DRG that included 
all the ICD-10 codes related to the complication. The 
costs of the DRGs selected were taken from the IMSS 
Medical-Economic Forms. Since diabetic amputations 
are defined as those hospitalisations where the main 
cause was any diabetic ICD-10 code where the patient 
suffered an amputation, only the cost of the surgical 
procedure was considered since this intervention rep-
resents additional costs not previously accounted for. 
The latter cost was obtained from a joint effort in 2012 
to produce maximum referral tariffs by the four main 
health care institutions in Mexico.16 Table I shows the 
DRG classification and costs for all the ICD-10 codes 
considered in this analysis.
 It is important to note that IMSS-DRG costs are cur-
rently used by IMSS as a reference and do not necessarily 
represent what IMSS hospitals are really expending on 
each treatment. In addition, IMSS-DRG costs do not con-
sider rural-urban nor big-small city price differentials. 
Despite these drawbacks of using IMSS-DRG costs as 
proxy of hospital care costs in local health ministries, 
they are still considered the best available costing data 
to conduct this study.
 The estimation of the health burden assumes that pa-
tients would not have experienced complications if they 
had received appropriate primary care and computes 
the associated Disability-Adjusted Life Years (DALYs). 
Disability weights for diabetic foot, neuropathy, kidney 
failure – stage IV, amputation of toe, amputation of one 
leg, and amputation of both legs were taken from the 
Global Burden of Disease Study 2010.17 The weight for 
retinopathy-blindness was taken from the Global Burden 
of Disease 2004 Update, since the 2010 version did not 
report a weight for this condition.18 Due to lack of detail 
concerning the severity of the condition from hospital-
ised patients (e.g. degree of kidney failure or seriousness 
of retinopathy) and the absence of disability weights 
for different severity levels, only one level of disability 
(equal to the available weight in each case) is considered 
for patients whose main hospitalisation diagnosis was 
kidney failure, retinopathy, neuropathy and diabetic 
foot. This clearly overestimates the DALYs associated 
with these conditions and, thus, should be interpreted as 
the upper bound of the health burden of ACSHs result-
ing from diabetic complications. WHO data on the life 
expectancy at age with the lowest mortality observed 
worldwide are used to compute the Years of Life Lost 
(YLL) and Years Lived with Disability (YLD).13,19
 Some hospitalised patients whose main diagnosis 
was kidney failure, neuropathy, retinopathy and dia-
betic foot also suffered amputations. Hence, to avoid 
double counting of deaths while computing YLL it 
was necessary to define the variable “net amputa-
tion” indicating those diabetic amputations in which 
the main hospitalisation cause was none of the other 
Table I
Diabetic icD-10 coDes anD DRG classification
ICD-10 of Diabetic Complications DRG IMSS DRG 2013 Cost (MXN)
Kidney Failure E10.2, E11.2, E12.2, E13.2, E14.2 698 – Other kidney and urinary tract diagnostics with 
major complications
71 066
Retinopathy E10.3, E11.3, E12.3, E13.3, E14.3 125 – Other eye disorders 22 820
Neuropathy E10.4, E11.4, E12.4, E13.4, E14.4 074 – Cranial and peripheral nerve disorders with no 
major complications
37 494
Diabetic Foot E10.5, E11.5, E12.5, E13.5, E14.5 301 – Peripheral vascular disorders 46 057
Amputation Any Diabetic code + CIE-9CM: 84.1, 84.10, 84.11, 
84.14, 84.15, 84.17, 84.19
Low limb amputation secondary to diabetic foot 58 831
All Diabetic Hospitalisations ICD-10 Codes
E10.9, E11.9, E12.9, E13.9, E14.9, E10.0, E10.1, E10.6, E10.7, E10.8, E11.0, E11.1, E11.6, E11.7, E11.8, E12.0, E12.1, E12.6, E12.7, E12.8, E13.0, E13.1, E13.6, E13.7, E13.8, 
E14.0, E14.1, E14.6, E14.7, E14.8, E10.5, E11.5, E12.5, E13.5, E14.5, E10.3, E11.3, E12.3, E13.3, E14.3, E10.2, E11.2, E12.2, E13.2, E14.2, E10.4, E11.4, E12.4, E13.4, E14.4 
Source: References 2 and 15. IMSS, Cédulas Médico-Económicas. México DF, 2014
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complications analysed; therefore, amputation YLL are 
based on net amputations. However, when computing 
YLD the total number of people suffering amputa-
tions was used, since amputations will contribute to 
their disability; in this case, patients with diabetic foot 
without amputations (net diabetic foot) were used to 
compute diabetic foot YLD.
Results
Table II shows the composition of ACSHs due to dia-
betic complications during 2001-2011. A total of 195 778 
hospitalisations met the described criteria and account 
for 52% of total diabetic ACSHs and 21% of total ACSHs 
identified by Lugo-Palacios and Cairns.2 Total ACSHs 
due to diabetic complications increased by more than 
130% over the period. While kidney failure and ampu-
tation discharges seemed to reach a plateau after 2008, 
hospitalisations for diabetic foot increased throughout 
the whole period (by 163% overall). 
Financial costs
Table III shows the estimated financial costs of ACSHs 
as a result of diabetic complications. Scenario 1 uses the 
full IMSS-DRG costs as proxy for local health ministries’ 
hospital care costs; Scenario 2 uses adjusted costs as 
described previously.
 Financial costs of ACSH due to diabetic complica-
tions increased 125% in real terms during 2001-2011. 
Measured as cost per person with no social security 
(major demanders of the services provided by the ana-
lysed hospitals), the costs in scenario 1 increased by 
95.4% from 11.04 MXN in 2001 to 21.6 MXN in 2011. 
Diabetic foot hospitalisation costs exhibit a continuous 
increasing trend throughout the period growing by more 
than 160% and surpassed kidney failure hospitalisations 
from 2010 onwards as the most important contributor 
to the cost of ACSHs from diabetic complications; by 
2011 diabetic foot hospitalisation costs were more than 
80 times the retinopathy costs and more than 30 the 
neuropathy costs. 
Health burden
The estimated DALYs associated with diabetic com-
plications ACSH are presented in table IV. Overall, 
DALYs increased by 112% in 2001-2011. Kidney failure 
is the complication with the highest health burden. In 
2011, DALYs associated with diabetic amputation (the 
complication with the second highest health burden) 
represented only 29% of the kidney failure DALYs. 
 During the study period, the difference between the 
health burden caused by kidney failure and the burden 
associated with the rest of the complications increased. 
However, YLL and YLD show different trends during 
this period (the disaggregation of DALYs in YLL and 
YLD is available upon request). On the one hand, the 
difference between kidney failure YLL and the second 
cause of YLL, diabetic foot, rose 161% with this gap 
broadening in the last three years due to a continuous 
increase in kidney failure YLL and a stable trend in 
diabetic foot YLL. On the other hand, the difference 
between kidney failure YLD and the second cause of 
Table II
Diabetic acsHs in Mexico 2001-2011. Hospital DiscHaRGes
Complication 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Total
             
Kidney failure 3 682 4 045 4 330 4 332 4 900 5 142 5 835 7 006 6 987 6 640 6 563 59 462
Retinopathy 130 140 128 96 175 221 174 175 158 138 292 1 827
Neuropathy 274 318 279 362 407 412 353 429 466 422 432 4 154
Diabetic foot 4 520 5 140 5 717 6 056 6 815 7 468 8 243 9 461 10 139 11 352 11 883 86 794
Amputation* 2 215 2 386 2 897 3 092‡ 3 505 3 863 4 110 4 831 4 941 5 806 5 895 43 541
Total 10 821 12 029 13 351 13 938 15 802 17 106 18 715 21 902 22 691 24 358 25 065 195 778
Source: Authors using data from Sistema Nacional de Información en Salud14 
Notes: 
* Some diabetic patients suffered more than one amputation. In that case, they are counted as different surgical procedures, but only contributed with one 
discharge to their hospitalisation type (for example, one patient with diabetic foot had two different amputations, they are counted as two amputations 
procedures but only one diabetic foot discharge)
‡ In 2004, only 129 amputations were reported. However, this number is not consistent with the observed trend possibly due to an error in the records. The 
number used in this study was imputed by obtaining the average for 2003 and 2005 of the ratio of amputation procedures to total diabetic foot hospitalisa-
tions. The 2004 ratio used is less than one standard deviation from the mean of the values observed in 2001-2003 and 2005-2011
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YLD, amputation, grew 15% during 2001-2011, but in 
the last four years this difference narrowed as the trend 
in kidney failure YLD remained relatively stable while 
the amputation YLD experienced a 26% increase.
 With the exception of neuropathy, the health burden 
of all complications increased by more than 100%; the 
most dramatic increment was amputation DALYs which 
increased by 142% from more than 5 000 DALYs in 2001 
to almost 13 000 in 2011.
 Figure 1 presents, graphically, the behaviour of the 
financial and health burden for each of the complications 
analysed. It shows that both financial and health bur-
Table IV
Disability aDjusteD life yeaRs (Dalys) associateD witH Diabetic coMplications acsH. Mexico 
2001-2011.*
Complications 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Kidney failure 21 517 24 450 24 790 25 199 29 734 30 258 35 295 45 165 43 421 42 623 44 356
Retinopathy 2 526 2 954 2 417 1 877 3 384 3 954 3 285 3 366 3 026 2 528 5 457
Neuropathy 1 236 1 217 1 145 1 420 1 534 1 728 1 612 1 875 2 208 2 135 1 941
Diabetic foot 3 415 5 194 4 505 4 646 3 692 5 330 5 900 6 107 7 120 7 431 7 410
Amputation 5 372 5 683 7 289 7 902‡ 8 303 9 310 9 192 11 684 11 227 13 295 12 976
Total 34 067 39 498 40 145 41 044 46 647 50 580 55 284 68 197 67 002 68 013 72 140
Notes: 
* Disaggregation of DALYs in years of life lost (YLL) and years lived with disability (YLD) is available upon request
‡ In 2004 only 129 amputations were reported. However, this number is not consistent with the observed trend possibly due to an error in the records. The 
number used in this study was imputed by obtaining the average for 2003 and 2005 of the ratio of amputation procedures to total diabetic foot hospitalisa-
tions. For computing the years of life lost, the average for 2003 and 2005 of the ratio yll amputation to yll diabetic foot was used in 2004. For computing YLD 
(both for amputation and diabetic foot), the average of observed values in 2003 and 2005 was used because net diabetic foot is affected by amputations and 
if the latter is underestimated the former will be over recorded
Table III
financial acsH cost (2011 Million Mxn*)
Complication 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Scenario 1: Full IMSS DRG Cost            
     Kidney failure 243.01 266.97 285.79 285.92 323.40 339.36 385.10 462.39 461.12 438.21 433.13
     Retinopathy 2.76 2.97 2.71 2.03 3.71 4.68 3.69 3.71 3.35 2.92 6.19
     Neuropathy 9.54 11.07 9.72 12.61 14.17 14.35 12.29 14.94 16.23 14.69 15.04
     Diabetic foot 193.34 219.85 244.54 259.04 291.50 319.42 352.57 404.67 433.66 485.53 508.25
     Amputation 121.02 130.36 158.29 168.92 191.50 211.05 224.55 263.95 269.95 317.20 322.07
     Total 569.66 631.22 701.04 728.52 824.28 888.86 978.20 1 149.66 1 184.30 1 258.56 1 284.68
            
Scenario 2: 56% of IMSS DRG Cost‡          
     Kidney failure 136.09 149.50 160.04 160.11 181.10 190.04 215.65 258.94 258.23 245.40 242.56
     Retinopathy 1.54 1.66 1.52 1.14 2.08 2.62 2.07 2.08 1.88 1.64 3.47
     Neuropathy 5.34 6.20 5.44 7.06 7.94 8.03 6.88 8.37 9.09 8.23 8.42
     Diabetic foot 108.27 123.12 136.94 145.06 163.24 178.87 197.44 226.62 242.85 271.90 284.62
     Amputation 67.77 73.00 88.64 94.60 107.24 118.19 125.75 147.81 151.17 177.63 180.36
     Total 319.01 353.49 392.58 407.97 461.59 497.76 547.79 643.81 663.21 704.80 719.42
Notes: 
* 2013 IMSS DRG costs were transformed to 2011 MXN using annual inflation rates published by the National Institute of Geography and Statistics - INEGI 
(available in: http://www.inegi.org.mx/sistemas/indiceprecios/CalculadoraInflacion.aspx ). The only change assumed in the costs during this period was inflation
‡ 56% of the cost of each of the IMSS DRGs selected was used to obtain Scenario 2 results, adjusting by the cost-differential suggested by Arredondo and 
De Icaza9
Artículo originAl
38 salud pública de méxico / vol. 58, no. 1, enero-febrero de 2016
Lugo-Palacios DG, Cairns J
den for kidney failure and amputation seemed to have 
reached a plateau in the last four years. Diabetic foot and 
retinopathy show no major changes in the health burden 
in the last years of the period although their financial 
cost rose, especially in the case of diabetic foot. 
Discussion
Despite promotion and prevention efforts to improve 
the control of diabetes across the Mexican health system, 
the financial and the health burden of ACSH associated 
with diabetic complications increased dramatically in 
2001-2011. Some factors, not necessarily related to the 
effectiveness of primary care, can explain this rise. 
First, the prevalence of the disease grew importantly 
from 5.8% in 2000 to 9.17% in 2012, thus, increasing the 
demand for diabetes care.20 Second, the gradual health 
insurance expansion fostered by the 2003 Health Reform 
improved access for people with poorly controlled 
chronic conditions for whom preventable hospitalisa-
tions could not be avoided by the time they sought 
health care.2 However, whether or not the ACSH rate 
is a valid indicator of the performance of an expanding 
primary care system, the financial and health burden of 
ACSHs requires attention since this double burden high-
lights an inefficient use of health resources and should 
be seen as a future reallocation target to improve the 
value for the money invested in health care in Mexico. 
 This paper found that financial costs of ACSH as-
sociated with diabetic complications have continuously 
increased but that the trend differs by complication. It 
is worth highlighting that the most worrying case is 
the one of diabetic foot, a complication that can eas-
ily be avoided through basic primary care but that it 
is still the leading cause of hospitalisation among the 
complications analysed; moreover, in 2010 and 2011 this 
complication became the most costly of the ACSHs due 
to diabetic complications.
 It is important to emphasise the relevance of the 
magnitude of the financial costs of diabetic ACSH within 
the Mexican context. The estimated costs under Scenario 
1 reached in 2011 almost MXN 1 300 million (approxi-
mately 105 million USD) equivalent to the Seguro Popular 
federal transfers to the state of Tabasco in that year (that 
had at that time more than 1.5 million Seguro Popular 
beneficiaries) and to 0.83% of the total direct costs of 
fiGuRe 1. financial cost anD HealtH buRDen of Diabetic acsH. Mexico 2001-2011
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treating the main complications of diabetes in 2013 in 
Mexico estimated by Barraza-Lloréns and colleagues.10,21
 As a novel approach to ACSH, this paper also 
estimated the health burden of diabetic complications 
ACSH. In 2010, this health burden was estimated to be 
more than 68 000 DALYs accounting for 4.2% of total 
DALYs associated with diabetes in Mexico.13 
 Given the WHO cost-effectiveness criterion (an 
intervention is highly cost-effective if the cost of avert-
ing one DALY is less than or equal to GDP per capita), 
in 2011 it would have been cost-effective to spend up 
to $(Int) 1 146.1 million on primary care interventions 
that could avert the DALYs associated with diabetic 
complications; if DALYs are discounted at the annual 
rate of 3%, then the threshold is $(Int) 718.4 million ($Int 
stands for 2011 international dollars).22 This approach 
clearly highlights the importance of the health burden 
of diabetic ACSHs.
 The present paper is subject to the following limita-
tions. First, due to the lack of cost data from local health 
ministries, IMSS-DRG costs were used as proxy which 
could represent an overestimate of the real hospitalisa-
tion costs observed in local health ministries. With the 
intention of alleviating the potential bias, this paper 
followed Arredondo and De Icaza and assumed that 
costs at local health ministries are 56% of IMSS costs. 
Second, this study assumes a homogenous system in 
the provision of care when in practice there are 32 sub-
systems (one per state) that can face different costs and 
different diabetes prevalence rates.20 Consequently this 
analysis may over-estimate the hospitalisation costs in 
some areas and under-estimate them in others. For this 
reason, figures are reported at the national level such 
that, on average, these over-and underestimations are 
balanced. Third, this analysis does not estimate the 
indirect costs of diabetic ACSH that would include the 
productivity implications of premature mortality, per-
manent and temporary disability. Fourth, given that the 
hospital discharge database does not record the severity 
of the condition for which patients were hospitalised, 
and also owing to the lack of disability weights for 
different severity levels of certain conditions, such as 
kidney failure and retinopathy, all kidney failure and 
retinopathy admissions were assumed to have the same 
severity level: stage IV and blindness, respectively. This 
assumption clearly overestimates the associated DALYs 
and, therefore, should be taken as an upper bound of 
the health burden associated with ACSH due to diabetic 
complications, a sensitivity analysis of this assumption 
is available upon request. Fifth, since it is not possible to 
identify when a patient was discharged more than once 
in the same year or during the study period, DALYs will 
be double-counted when patients are admitted more 
than once for the same cause. Finally, DALYs may also 
be overestimated due to the assumption that a compli-
cation avoided in one period is avoided for the rest of 
the patient’s life.
 Avoiding preventable hospitalisations potentially 
releases resources within the health system making 
them available for other health purposes, but providing 
the services that could prevent these hospitalisations 
implies investment in primary care not taken into ac-
count in this study. This paper showed that the health 
burden associated with diabetic ACSHs is important 
and should be consider, in addition to financial costs, in 
primary care decision making. Sound evidence of what 
works to prevent ACSHs is crucial to ensure the efficient 
allocation of resources in primary care. Therefore, fur-
ther research on the evaluation of national campaigns 
aiming to improve both the delivery of primary care 
and patients’ adherence to treatments that consider both 
the financial and the health burden of ACSH is needed 
to better understand the extent to which Mexicans are 
getting value for their money invested in health. 
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